Quarterly report pursuant to Section 13 or 15(d)

Condensed Statements of Operations

v3.23.1
Condensed Statements of Operations - USD ($)
3 Months Ended
Mar. 31, 2023
Mar. 31, 2022
Operating expenses:    
Research and development $ 497,714 $ 2,769,102
General and administrative expenses 1,059,573 1,192,112
Total operating expenses 1,557,287 3,961,214
Loss from operations (1,557,287) (3,961,214)
Other income:    
Interest income 40,423 906
Total other income 40,423 906
Loss before income taxes (1,516,864) (3,960,308)
Net loss $ (1,516,864) $ (3,960,308)
Basic net loss per share $ (0.08) $ (0.48)
Diluted net loss per share $ (0.08) $ (0.48)
Weighted average number of shares outstanding - basic 18,330,390 8,330,390
Weighted average number of shares outstanding - diluted 18,330,390 8,330,390